Literature DB >> 20142731

Histopathologic basis for the favorable survival after resection of intraductal papillary mucinous neoplasm-associated invasive adenocarcinoma of the pancreas.

George A Poultsides1, Sushanth Reddy, John L Cameron, Ralph H Hruban, Timothy M Pawlik, Nita Ahuja, Ajay Jain, Barish H Edil, Christine A Iacobuzio-Donahue, Richard D Schulick, Christopher L Wolfgang.   

Abstract

OBJECTIVE: To identify pathologic features that may account for the favorable survival after resection of invasive pancreatic adenocarcinoma arising in the setting of intraductal papillary mucinous neoplasm (IPMN) compared with standard pancreatic ductal adenocarcinoma (PDA) in the absence of IPMN. SUMMARY BACKGROUND DATA: The 5-year survival after resection of IPMN-associated invasive adenocarcinoma is reported to be between 40% and 60%, which is superior to the 10-25%, typically cited after resection of standard PDA. It remains unclear whether this represents distinct biology or simply a tendency for earlier presentation of IPMN-associated invasive adenocarcinoma.
METHODS: A single institution's prospective pancreatic resection database was retrospectively reviewed to identify patients with invasive pancreatic adenocarcinoma who underwent pancreatectomy with curative intent. Log rank and Cox regression analysis were used to identify factors associated with survival.
RESULTS: From 1995 to 2006, 1260 consecutive patients were identified, 132 (10%) with IPMN-associated invasive adenocarcinoma and 1128 (90%) with standard PDA. Actuarial 5-year survival was 42% after resection for IPMN-associated versus 19% for standard PDA (P < 0.001). However, compared with standard PDA, invasive adenocarcinoma arising within an IPMN was associated with a lower incidence of (1) advanced T stage (T2-T4, 96% vs. 73%, P < 0.001); (2) regional lymph node metastasis (78% vs. 51%, P < 0.001); (3) poor tumor differentiation (44% vs. 26%, P < 0.001); (4) vascular invasion (54% vs. 33%, P < 0.001); (5) perineural invasion (92% vs. 63%, P < 0.001); and (6) microscopic margin involvement (28% vs. 14%, P < 0.001). Specifically, in the presence of any one of the aforementioned adverse pathologic characteristics, outcomes after resection for IPMN-associated and standard PDA were not significantly different.
CONCLUSION: The favorable biologic behavior of IPMN-associated compared with standard PDA is based on its lower rate of advanced T stage, lymph node metastasis, high tumor grade, positive resection margin, perineural, and vascular invasion. In the presence of any one of the aforementioned adverse pathologic characteristics, however, survival outcomes after resection of IPMN-associated and after resection of standard pancreatic adenocarcinoma are similar.

Entities:  

Mesh:

Year:  2010        PMID: 20142731      PMCID: PMC3437748          DOI: 10.1097/SLA.0b013e3181cf8a19

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  21 in total

1.  Almost all infiltrating colloid carcinomas of the pancreas and periampullary region arise from in situ papillary neoplasms: a study of 39 cases.

Authors:  Gregory Seidel; Marianna Zahurak; Christine Iacobuzio-Donahue; Taylor A Sohn; N Volkan Adsay; Charles J Yeo; Keith D Lillemoe; John L Cameron; Ralph H Hruban; Robb E Wilentz
Journal:  Am J Surg Pathol       Date:  2002-01       Impact factor: 6.394

2.  Intraductal papillary mucinous neoplasms of the pancreas: an increasingly recognized clinicopathologic entity.

Authors:  T A Sohn; C J Yeo; J L Cameron; C A Iacobuzio-Donahue; R H Hruban; K D Lillemoe
Journal:  Ann Surg       Date:  2001-09       Impact factor: 12.969

3.  Colloid (mucinous noncystic) carcinoma of the pancreas.

Authors:  N V Adsay; C Pierson; F Sarkar; J Abrams; D Weaver; K C Conlon; M F Brennan; D S Klimstra
Journal:  Am J Surg Pathol       Date:  2001-01       Impact factor: 6.394

4.  Prognosis of malignant intraductal papillary mucinous tumours of the pancreas after surgical resection. Comparison with pancreatic ductal adenocarcinoma.

Authors:  F Maire; P Hammel; B Terris; F Paye; J-Y Scoazec; C Cellier; M Barthet; D O'Toole; P Rufat; C Partensky; E Cuillerier; P Lévy; J Belghiti; P Ruszniewski
Journal:  Gut       Date:  2002-11       Impact factor: 23.059

5.  Molecular progression of promoter methylation in intraductal papillary mucinous neoplasms (IPMN) of the pancreas.

Authors:  Michael G House; MingZhou Guo; Christine Iacobuzio-Donahue; James G Herman
Journal:  Carcinogenesis       Date:  2003-02       Impact factor: 4.944

6.  Pathogenesis of colloid (pure mucinous) carcinoma of exocrine organs: Coupling of gel-forming mucin (MUC2) production with altered cell polarity and abnormal cell-stroma interaction may be the key factor in the morphogenesis and indolent behavior of colloid carcinoma in the breast and pancreas.

Authors:  N Volkan Adsay; Kambiz Merati; Hind Nassar; Jinru Shia; Fazlul Sarkar; Christopher R Pierson; Jeanette D Cheng; Daniel W Visscher; Ralph H Hruban; David S Klimstra
Journal:  Am J Surg Pathol       Date:  2003-05       Impact factor: 6.394

7.  Hypermethylation of multiple genes in pancreatic adenocarcinoma.

Authors:  T Ueki; M Toyota; T Sohn; C J Yeo; J P Issa; R H Hruban; M Goggins
Journal:  Cancer Res       Date:  2000-04-01       Impact factor: 12.701

8.  Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection.

Authors:  Roberto Salvia; Carlos Fernández-del Castillo; Claudio Bassi; Sarah P Thayer; Massimo Falconi; William Mantovani; Paolo Pederzoli; Andrew L Warshaw
Journal:  Ann Surg       Date:  2004-05       Impact factor: 12.969

9.  Intraductal papillary mucinous neoplasms of the pancreas: an analysis of clinicopathologic features and outcome.

Authors:  Michael D'Angelica; Murray F Brennan; Arief A Suriawinata; David Klimstra; Kevin C Conlon
Journal:  Ann Surg       Date:  2004-03       Impact factor: 12.969

10.  Global genomic analysis of intraductal papillary mucinous neoplasms of the pancreas reveals significant molecular differences compared to ductal adenocarcinoma.

Authors:  Stefan Fritz; Carlos Fernandez-del Castillo; Mari Mino-Kenudson; Stefano Crippa; Vikram Deshpande; Gregory Y Lauwers; Andrew L Warshaw; Sarah P Thayer; A John Iafrate
Journal:  Ann Surg       Date:  2009-03       Impact factor: 12.969

View more
  71 in total

Review 1.  Intraductal papillary mucinous neoplasia (IPMN) of the pancreas: its diagnosis, treatment, and prognosis.

Authors:  Robert Grützmann; Stefan Post; Hans Detlev Saeger; Marco Niedergethmann
Journal:  Dtsch Arztebl Int       Date:  2011-11-18       Impact factor: 5.594

2.  Invasive intraductal papillary mucinous neoplasm: predictors of survival and role of adjuvant therapy.

Authors:  Olivier Turrini; Joshua A Waters; Thomas Schnelldorfer; Keith D Lillemoe; Constantin T Yiannoutsos; Michael B Farnell; Michael G Sarr; C Max Schmidt
Journal:  HPB (Oxford)       Date:  2010-09       Impact factor: 3.647

Review 3.  IPMN: surgical treatment.

Authors:  Reto M Käppeli; Sascha A Müller; Bianka Hummel; Christina Kruse; Philip Müller; Jürgen Fornaro; Alexander Wilhelm; Marcel Zadnikar; Bruno M Schmied; Ignazio Tarantino
Journal:  Langenbecks Arch Surg       Date:  2013-09-03       Impact factor: 3.445

Review 4.  [Surgical therapy of intraductal papillary mucinous neoplasms of the pancreas].

Authors:  S Fritz; M W Büchler; J Werner
Journal:  Chirurg       Date:  2012-02       Impact factor: 0.955

Review 5.  Pancreatic cancer from bench to bedside: molecular pathways and treatment options.

Authors:  Christoforos Kosmidis; Konstantinos Sapalidis; Efstathios Kotidis; Nikolaos Mixalopoulos; Paul Zarogoulidis; Drosos Tsavlis; Sofia Baka; Yan-Gao Man; John Kanellos
Journal:  Ann Transl Med       Date:  2016-05

6.  Colloid carcinoma of the pancreas.

Authors:  Timothy A Plerhoples; Michael Ahdoot; Michael A DiMaio; Reetesh K Pai; Walter G Park; George A Poultsides
Journal:  Dig Dis Sci       Date:  2011-01-21       Impact factor: 3.199

7.  Multi-institutional Validation Study of Pancreatic Cyst Fluid Protein Analysis for Prediction of High-risk Intraductal Papillary Mucinous Neoplasms of the Pancreas.

Authors:  Mohammad A Al Efishat; Marc A Attiyeh; Anne A Eaton; Mithat Gönen; Denise Prosser; Anna E Lokshin; Carlos Fernández-Del Castillo; Keith D Lillemoe; Cristina R Ferrone; Ilaria Pergolini; Mari Mino-Kenudson; Neda Rezaee; Marco Dal Molin; Matthew J Weiss; John L Cameron; Ralph H Hruban; Michael I D'Angelica; T Peter Kingham; Ronald P DeMatteo; William R Jarnagin; Christopher L Wolfgang; Peter J Allen
Journal:  Ann Surg       Date:  2018-08       Impact factor: 12.969

8.  The chromatin regulator Brg1 suppresses formation of intraductal papillary mucinous neoplasm and pancreatic ductal adenocarcinoma.

Authors:  Guido von Figura; Akihisa Fukuda; Nilotpal Roy; Muluye E Liku; John P Morris Iv; Grace E Kim; Holger A Russ; Matthew A Firpo; Sean J Mulvihill; David W Dawson; Jorge Ferrer; William F Mueller; Anke Busch; Klemens J Hertel; Matthias Hebrok
Journal:  Nat Cell Biol       Date:  2014-02-23       Impact factor: 28.824

9.  Pathologic Evaluation and Reporting of Intraductal Papillary Mucinous Neoplasms of the Pancreas and Other Tumoral Intraepithelial Neoplasms of Pancreatobiliary Tract: Recommendations of Verona Consensus Meeting.

Authors:  Volkan Adsay; Mari Mino-Kenudson; Toru Furukawa; Olca Basturk; Giuseppe Zamboni; Giovanni Marchegiani; Claudio Bassi; Roberto Salvia; Giuseppe Malleo; Salvatore Paiella; Christopher L Wolfgang; Hanno Matthaei; G Johan Offerhaus; Mustapha Adham; Marco J Bruno; Michelle D Reid; Alyssa Krasinskas; Günter Klöppel; Nobuyuki Ohike; Takuma Tajiri; Kee-Taek Jang; Juan Carlos Roa; Peter Allen; Carlos Fernández-del Castillo; Jin-Young Jang; David S Klimstra; Ralph H Hruban
Journal:  Ann Surg       Date:  2016-01       Impact factor: 12.969

Review 10.  Pathological and molecular evaluation of pancreatic neoplasms.

Authors:  Arvind Rishi; Michael Goggins; Laura D Wood; Ralph H Hruban
Journal:  Semin Oncol       Date:  2014-12-09       Impact factor: 4.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.